Phase 1 Trial of Nab-Paclitaxel PIPAC (Pressurized Intraperitoneal Aerosolized Chemotherapy) Given in Combination With Second-Line Therapy for Gastric Cancer With Peritoneal Metastases

This phase I trial tests the safety, side effects and best dose of nab-paclitaxel pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in combination with second-line chemotherapy, paclitaxel and ramucirumab, and tests how well they work in treating stomach cancer that has spread from where it first started to the tissue that lines the abdominal wall and organs (peritoneal metastases). Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. PIPAC delivers chemotherapy, such as nab-paclitaxel, that has been turned into a fine mist (aerosolized) at a high pressure directly into the abdominal cavity. Aerosolized chemotherapy delivered directly into the peritoneal space has been shown to deliver higher drug concentrations to the tumor. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving nab-paclitaxel PIPAC in combination with paclitaxel and ramucirumab may be safe, tolerable, and/or effective in treating gastric cancer patients with peritoneal metastases.

Start Date17 Oct 2025

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT06393751

/ Not yet recruitingPhase 1/2IIT

A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer

This phase I/II trial tests the safety, best dose and effectiveness of adding tolinapant (ASTX660) to paclitaxel with or without bevacizumab in treating patients with ovarian cancer that has come back after a period of improvement (recurrent). Tolinapant may stop the growth of tumor cells by blocking proteins, such as XIAP and cIAP1, that promote the growth of tumor cells and increase resistance to chemotherapy. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of tumor cells. Adding ASTX660 to paclitaxel with or without bevacizumab may be safe, tolerable and/or effective in treating patients with recurrent ovarian cancer.

Start Date02 May 2025

Sponsor / Collaborator

National Cancer Institute

NCT05312372

/ WithdrawnPhase 1/2IIT

A Phase 1/2, Open -Label, Multicenter Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antineoplastic Activity of S095033 (MAT2A Inhibitor) in Combination With Paclitaxel in Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

The purpose of this study is to determinate the safety profile, tolerability, pharmacokinetics, and preliminary antineoplastic activity of S095033 in combination with paclitaxel in participants with advanced or metastatic esophageal squamous cell carcinoma (ESCC)

Start Date01 May 2025

Sponsor / Collaborator

Institut de Recherches Intern Servier

[+1]

100 Clinical Results associated with Paclitaxel

100 Translational Medicine associated with Paclitaxel

100 Patents (Medical) associated with Paclitaxel

43,190

Literatures (Medical) associated with Paclitaxel

01 Dec 2025·Journal of Gastrointestinal Cancer

Network Meta-analysis of Randomized Controlled Trials in Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Comparisons Involving Ramucirumab

Review

Author: Taipale, Kaisa ; Paine, Abby ; Gupta, Palvi ; D'yachkova, Yulia ; Liepa, Astra M ; Earley-Valovic, Veronika ; Goel, Rajat

PURPOSE:

With relatively few direct comparisons among treatment options for previously treated advanced gastric cancer or gastroesophageal junction (GEJ) cancer, network meta-analysis (NMA) may inform evidence-based decision-making. Ramucirumab plus paclitaxel (RAM + PTX) is a preferred regimen in guideline recommendations. NMA of key outcomes may further characterize the relative clinical value of RAM + PTX.

METHODS:

A systematic literature review of randomized controlled trials of adult patients with previously treated advanced gastric/GEJ cancer informed a NMA which compared overall survival, progression-free survival, and discontinuations due to adverse events. Comparisons were reported relative to placebo/best supportive care (BSC) when possible, otherwise relative to RAM + PTX.

RESULTS:

The base-case NMA focused on second-line treatment only, from 19 of 28 studies identified. For overall survival, seven of 16 regimens were favorable relative to placebo/BSC, with RAM + PTX as the most favorable. For progression-free survival, five of 14 regimens were unfavorable relative to RAM + PTX. For discontinuations due to adverse events, two of 13 regimens were similar to placebo/BSC: ramucirumab monotherapy and fluorouracil; relative to RAM-PTX, all regimens were similar except ramucirumab monotherapy which was favorable and irinotecan + cisplatin which was unfavorable.

CONCLUSION:

This NMA of trials of previously treated gastric/GEJ cancer suggests that RAM + PTX has one of the more favorable clinical profiles.

01 Apr 2025·Cancer Genetics

Prognosis prediction and drug guidance of ovarian serous cystadenocarcinoma through mitochondria gene-based model

Article

Author: Guo, Yi ; Chen, Zhenghu ; Tong, Xiaowen ; Li, Huaifang ; Chen, Meiyi ; Wu, Chenghao ; Zhou, Zixuan ; Shen, Dongsheng

BACKGROUND:

Mitochondrial dysregulation contributes to the chemoresistance of multiple cancer types. Yet, the functions of mitochondrial dysregulation in Ovarian serous cystadenocarcinoma (OSC) remain largely unknown.

AIM:

We sought to investigate the function of mitochondrial dysregulation in OSC from the bioinformatics perspective. We aimed to establish a model for prognosis prediction and chemosensitivity evaluation of the OSC patients by targeting mitochondrial dysregulation.

METHODS:

Differentially expressed genes (DEGs) were screened from the Cancer Genome Atlas (TCGA)-OV dataset and the mitochondrial-related DEGs were identified from the Human MitoCarta 3.0 database. Prognosis-related mitochondria-related genes (MRGs) were screened to establish the MRGs-based risk score model for prognosis prediction. To validate the risk score model, the risk score model was then evaluated by IHC staining intensity and survival curves from clinical specimens of OSC patients. Migration and proliferation assays were performed to elucidate the role of carcinogenic gene ACSS3 in serous ovarian cancer cell lines.

RESULTS:

Using consensus clustering algorithm, we identified 341 MRGs and two subtypes of OSC patients. Moreover, we established a novel prognostic risk score model by combining the transcription level, intensity and extent scores of MRGs for prognosis prediction purpose. The model was established using 7 MRGs (ACOT13, ACSS3, COA6, HINT2, MRPL14, NDUFC2, and NDUFV2) significantly correlated to the prognosis of OSC. Importantly, by performing the drug sensitivity analysis, we found that the OSC patients in the low-risk group were more sensitive to cisplatin, paclitaxel and docetaxel than those in the high-risk group, while the latter ones were more sensitive to VEGFR inhibitor Axitinib and BRAF inhibitors Vemurafenib and SB590885. In addition, patients in the low-risk group were predicted to have better response in anti-PD-1 immunotherapy than those in the high-risk group. The risk score model was then validated by survival curves of high-risk and low-risk groups determined by IHC staining scores of OSC clinical samples. The carcinogenic effect of ACSS3 in OSC was confirmed through the knockdown of ACSS3 in SKOV3 and HO-8910 cells.

CONCLUSION:

To summarize, we established a novel 7 MRGs - based risk score model that could be utilized for prognosis prediction and chemosensitivity assessment in OSC patients.

01 Apr 2025·Non-coding RNA Research

Targeting NUCKS1 with a fragment of tRNAAsn(GUU) of Chinese yew for the treatment of colorectal cancer

Article

Author: Cao, Kai-Yue ; Bai, Long-Bo ; Jiang, Zhi-Hong ; Zhang, Da ; Chen, Yan ; Jiang, Yu-Yang ; Yan, Tong-Meng

Despite the discovery of numerous oncogenes in colorectal cancer (CRC), the development of associated drugs is limited, posing a significant challenge for CRC treatment. Identification of novel druggable targets is therefore crucial for the therapeutic development of CRC. Here, we report the first investigation on therapeutics targeting the potent oncogene NUCKS1 to suppress cancer progression. NUCKS1-orientated bioinformatics screening of NUCKS1 inhibitors from our library of tRNA fragments originated from medicinal plants identified tRF-T36, a 5' tRNA fragment of tRNA^Asn(GUU) of Chinese yew (Taxus chinensis), exhibiting stronger inhibitory effects than taxol against CRC progression. Mechanistically, tRF-T36 binds directly to the 3' UTR of NUCKS1 mRNA to downregulate its expressions via RNAi pathway. High-throughput RNA sequencing indicated that the downregulated NUCKS1 induced by tRF-T36 further inhibits PI3K/Akt pathway, as verified by the significantly efficacy decrease of tRF-T36 mimic in co-treatment with 740Y-P, an agonist of PI3K/Akt pathway. Collectively, our findings emphasize the importance of NUCKS1 as a promising druggable target for CRC. Furthermore, the present study provides the first siRNA sequence, tRF-T36 mimic, as small RNA drug candidate, thereby shedding light on CRC therapeutics.

1,112

News (Medical) associated with Paclitaxel

24 Jan 2025

·endpts.com

ALX Oncology to make case for accelerated approval with new evorpacept data in gastric cancer

ALX Oncology is forging ahead with a treatment approach that has long been abandoned by other drugmakers, eyeing a potential accelerated approval pathway for its CD47-targeting drug in gastric cancer after reporting more data from a Phase 2 trial. The biotech believes it may have a case for a speedier regulatory path or a Phase 3 trial with a “relatively tight” design, CEO Jason Lettmann told Endpoints News in an interview. This comes after last summer’s topline data readout that turned out to be less impressive than a previous interim readout . According to Phase 2 data presented Thursday at the ASCO Gastrointestinal Cancers Symposium in San Francisco, evorpacept plus Roche’s Herceptin, Eli Lilly’s Cyramza and paclitaxel chemotherapy reached 9.5 months of median progression-free survival in 48 patients with fresh HER2-positive biopsies versus 7.1 months for the three-drug control. But in the open-label trial, the difference in median PFS in the broader intent-to-treat population of 127 patients was much less marked, with the treatment arm hitting 7.5 months versus 7.4 months for the control group. There were a “significant number of patients who were HER2-negative” in the ITT group because they had an old biopsy, Lettmann told Endpoints. “To be blunt, our drug will not work very well when we don’t have HER2 expression,” he said. Hello, Debbie Peters You’re an essential part of the biopharma world. Share your voice on this important question to help shape our understanding of the industry. Can you help us out? Hello, Debbie Peters You’re an essential part of the biopharma world. Share your voice on this important question to help shape our understanding of the industry. Can you help us out? The company’s share price $ALXO was down by as much as 16% Thursday morning. Thursday’s data join a topline readout in July 2024, which showed the evorpacept regimen attained a 40.3% overall response rate versus 26.6% for control, with a p-value of 0.027. The ORR for the treatment arm was even higher in patients with fresh biopsies at 54.8%. At the time, ALX said it would start a Phase 3 trial by the end of 2024. But Lettmann explained that “we wanted to see PFS mature and we wanted to see this biomarker story fully fleshed out — we now have both of those.” The biotech expects to share details on Phase 3 timings and details after it gets more clarity from the FDA in the second quarter. Evorpacept belongs to a troubled drug class. Several other CD47 contenders have been dropped by their developers due to serious safety issues, often involving infections or respiratory side effects. These ill-fated candidates include Gilead’s magrolimab , which it acquired back in 2020 as part of a $4.9 billion buyout of Forty Seven. In the Phase 2 trial, the evorpacept combination was well-tolerated. ALX believes that evorpacept’s silenced Fc demain and the company’s specific choice of combinations could help avoid the usual pitfalls. “We block the ‘don’t eat me’ signal, and then we use an Fc-active antibody like Herceptin to provide the ‘eat me’ signal — we need both of those things working together to then drive efficacy,” Lettmann said.

Phase 2Clinical ResultPhase 3Acquisition

23 Jan 2025

·www.drugs.com

Perioperative Chemo With FLOT Ups Survival in Resectable Esophageal Cancer

THURSDAY, Jan. 23, 2025 -- For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) leads to improved survival compared with preoperative chemoradiotherapy, according to a study published in the Jan. 23 issue of the New England Journal of Medicine . Jens Hoeppner, M.D., from Bielefeld University in Detmold, Germany, and colleagues conducted a phase 3 multicenter trial involving patients with resectable esophageal adenocarcinoma who were randomly assigned to receive perioperative chemotherapy with FLOT plus surgery or preoperative chemoradiotherapy (radiotherapy at a dose of 41.4 Gy and carboplatin and paclitaxel) plus surgery (221 and 217 patients, respectively). Eligibility criteria included a primary tumor with clinical stage cT1 cN+, cT2-4a cN+, or cT2-4a cN0 disease. The primary end point was overall survival. The researchers found that overall survival at three years was 57.4 and 50.7 percent in the FLOT and preoperative-chemoradiotherapy groups, respectively, with a median follow-up of 55 months (hazard ratio for death, 0.70). At three years, progression-free survival was 51.6 and 35.0 percent in the FLOT and preoperative-chemoradiotherapy groups, respectively (hazard ratio for disease progression or death, 0.66). Among the patients who started the assigned treatment, grade 3 or higher adverse events occurred in 58.0 and 50.0 percent of those in the FLOT and preoperative-chemoradiotherapy groups, respectively. "The current trial showed superior overall survival with FLOT as compared with preoperative chemoradiotherapy, with a median overall survival of 66 and 37 months, respectively," the authors write.

Clinical ResultPhase 3

23 Jan 2025

·ir.alxoncology.com

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trial Greatest benefit observed among patients with confirmed HER2-positive cancer, as demonstrated by either fresh biopsy or ctDNA HER2-expression, with confirmed ORR of 48.9% and mDOR of 15.7 months vs. 24.5% ORR and mDOR of 9.1 months in the control group, and a PFS Hazard Ratio of 0.64 Company to host conference call and investor webcast today at 1:00 PM PT/4:00 PM ET SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, announced positive updated data from the ASPEN-06 Phase 2 clinical trial demonstrating that the company’s investigational CD47-blocker evorpacept generates a durable clinical response with a well-tolerated safety profile among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The updated results, which build upon previously announced topline results, will be shared today in an oral presentation (Abstract #332) at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco. “The updated data from the ASPEN-06 trial highlight the potential clinical utility of CD47 inhibition from evorpacept in combination with trastuzumab, ramucirumab and paclitaxel in patients with previously treated HER2-positive gastric cancer,” said Kohei Shitara, M.D., Director of the Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan and the study’s presenter. “Overall, the findings suggest that evorpacept generates durable and clinically meaningful anti-tumor activity in this population of patients who had previously received a HER2-targeted agent, with the largest benefit among those patients with confirmed HER2-positive disease.” ASPEN-06 is a randomized, multi-center, international trial (NCT05002127) evaluating evorpacept, ALX Oncology’s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel (collectively, ETRP) against trastuzumab, ramucirumab and paclitaxel (TRP) alone for the treatment of patients with HER2-positive gastric/GEJ cancer, where all patients had received an anti-HER2 agent in prior lines of therapy. Patients were enrolled with either archival or fresh HER2-positive biopsies. The trial’s primary endpoints were investigator-assessed overall response rate (ORR) in the intent-to-treat (ITT) population and in the population of patients with fresh HER2-positive biopsies, compared to both internal control (TRP) and historical control (ramucirumab and paclitaxel, or RP). Key secondary endpoints were safety, duration of response (DOR), progression-free survival (PFS) and overall survival (OS). The updated dataset being presented today includes results from a December 2, 2024 data cut, including an analysis that assessed patients with HER2-positive tumors via circulating tumor DNA (ctDNA) at baseline. Overall survival data were not yet mature at the time of data cut. Updated trial results to be shared today at 2025 ASCO GI include: Primary endpoints (December data cut): ITT patient population ORR (N=127): Evorpacept plus TRP (ETRP) demonstrated an ORR of 41.3% compared to 30% for RP historical control and 26.6% for TRP control. Fresh HER2-positive biopsy patient population ORR (n=48): ETRP demonstrated an ORR of 59.1% compared to 30% for RP historical control and 23.1% for TRP control. In the ITT population, ETRP demonstrated a median DOR (mDOR) of 15.7 months and a median PFS (mPFS) of 7.5 months compared to an mDOR of 9.1 months and mPFS of 7.4 months in the TRP control group, with a PFS Hazard Ratio (HR) in this population of 0.77. In patients with fresh HER2-positive biopsies, ETRP demonstrated an mDOR of 15.7 months and mPFS of 9.5 months compared to an mDOR of 14.5 months and 7.1 months in the TRP control group, with a PFS HR of 0.62. In patients with confirmed HER2-positive expression as determined by either fresh biopsy or ctDNA HER2-positivity (n=96), the addition of evorpacept to TRP resulted in a 48.9% ORR, an mDOR of 15.7 months and mPFS of 7.5 months, compared to 24.5% ORR, an mDOR of 9.1 months and mPFS of 6.7 months in the TRP control group, with a PFS HR of 0.64. Evorpacept plus TRP was generally well tolerated, with the incidence of adverse events in the evorpacept population consistent with those in TRP control. ITT patient population ORR (N=127): Evorpacept plus TRP (ETRP) demonstrated an ORR of 41.3% compared to 30% for RP historical control and 26.6% for TRP control. Fresh HER2-positive biopsy patient population ORR (n=48): ETRP demonstrated an ORR of 59.1% compared to 30% for RP historical control and 23.1% for TRP control. “The results from this trial tell a clear story that when a cancer cell is expressing HER2, evorpacept can combine with a regimen containing an anti-HER2 antibody such as trastuzumab to improve upon the activity you would expect from that regimen alone,” said Alan Sandler, M.D., Chief Medical Officer at ALX Oncology. “This is evidenced by the near doubling of PFS at one year among the patients with HER2-positivity confirmed via either fresh biopsy or ctDNA who received ETRP vs control. Additionally, the analysis of this patient population affirms HER2-expression is a key biomarker for evorpacept efficacy and validates the strategy behind evorpacept’s novel design.” The updated ASPEN-06 data add to positive findings from a Phase 1b/2 trial recently presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). These findings suggested that patients with heavily pretreated HER2-positive advanced breast cancer had anti-tumor activity from CD47 inhibition with evorpacept when it is combined with a HER2-targeted agent. “The dataset shared today from the ASPEN-06 randomized clinical trial suggests durable clinical benefit driven by evorpacept and a differentiated safety profile – a first for any CD47 blocker,” said Jason Lettmann, Chief Executive Officer at ALX Oncology. “Based on the collective clinical data we’ve now seen across patients with HER2-positive gastric and breast cancers, we believe evorpacept is working as designed in combination with antibodies when there is HER2 expression, even when patients had been previously treated with other HER2-directed therapies. We look forward to sharing the updated ASPEN-06 data with the FDA and are confident in our path to pursue evorpacept as a therapeutic option for patients.” A copy of the 2025 ASCO GI presentation will be available in the “Publications” section of the ALX Oncology website following the presentation. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to evorpacept for the second-line treatment of patients with HER2-positive gastric or GEJ carcinoma. Additionally, both the FDA and European Commission have granted Orphan Drug Designation for this indication. Company Conference Call and Webcast on January 23 at 1:00 PM PT/4:00 PM ET ALX Oncology will host a conference call and webcast today at 1:00 PM PT/4:00 PM ET to review the updated ASPEN-06 data. The event will be webcast live and a replay will be available after the call by visiting the “Investors” section of ALX Oncology’s website and selecting “Events and Presentations”. Date & Time: Thursday, January 23, 1:00 PM PT/4:00 PM ET Webcast Access: https://edge.media-server.com/mmc/p/ipy66o44 About ALX Oncology ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology. Cautionary note regarding forward-looking statements This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (SEC), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations Contact: Elhan Webb, CFA, IR Consultant ewebb@alxoncology.com Media Contact: Audra Friis, Sam Brown, Inc. audrafriis@sambrown.com (917) 519-9577

Clinical ResultFast TrackASCOOrphan DrugPhase 2

100 Deals associated with Paclitaxel

External Link

KEGG	Wiki	ATC	Drug Bank
D00491	Paclitaxel	L01CD01	DB01229

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pancreatic adenocarcinoma metastatic	EU	Accord Healthcare SLU	05 Jan 2024
Pancreatic adenocarcinoma metastatic	IS	Accord Healthcare SLU	05 Jan 2024
Pancreatic adenocarcinoma metastatic	LI	Accord Healthcare SLU	05 Jan 2024
Pancreatic adenocarcinoma metastatic	NO	Accord Healthcare SLU	05 Jan 2024
Platinum-Resistant Primary Peritoneal Carcinoma	EU	Inceptua SA	20 Nov 2018
Platinum-Resistant Primary Peritoneal Carcinoma	IS	Inceptua SA	20 Nov 2018
Platinum-Resistant Primary Peritoneal Carcinoma	LI	Inceptua SA	20 Nov 2018
Platinum-Resistant Primary Peritoneal Carcinoma	NO	Inceptua SA	20 Nov 2018
Platinum-sensitive epithelial ovarian cancer	EU	Inceptua SA	20 Nov 2018
Platinum-sensitive epithelial ovarian cancer	IS	Inceptua SA	20 Nov 2018
Platinum-sensitive epithelial ovarian cancer	LI	Inceptua SA	20 Nov 2018
Platinum-sensitive epithelial ovarian cancer	NO	Inceptua SA	20 Nov 2018
Platinum-Sensitive Fallopian Tube Carcinoma	EU	Inceptua SA	20 Nov 2018
Platinum-Sensitive Fallopian Tube Carcinoma	IS	Inceptua SA	20 Nov 2018
Platinum-Sensitive Fallopian Tube Carcinoma	LI	Inceptua SA	20 Nov 2018
Platinum-Sensitive Fallopian Tube Carcinoma	NO	Inceptua SA	20 Nov 2018
Germinoma	JP	Clinigen KK	21 Feb 2013
Germinoma	JP	Bristol Myers Squibb Co.	21 Feb 2013
Esophageal Carcinoma	JP	Bristol Myers Squibb Co.	21 Mar 2012
Esophageal Carcinoma	JP	Clinigen KK	21 Mar 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	NDA/BLA	EU	Accord Healthcare SLU	09 Nov 2023
Metastatic Pancreatic Cancer	Phase 3	CN	Shanghai Yizhong Pharmaceutical Co., Ltd.	01 Feb 2025
High grade glioma	Phase 3	CN	Zhejiang University	01 Apr 2024
Human epidermal growth factor 2 negative carcinoma of breast	Phase 3	CN	Shanghai Yizhong Pharmaceutical Co., Ltd.	25 Sep 2023
Cutaneous Squamous Cell Carcinoma	Phase 3	US	National Cancer Institute	08 Jun 2023
Hypopharyngeal Carcinoma	Phase 3	US	National Cancer Institute	08 Jun 2023
Squamous cell carcinoma of head and neck metastatic	Phase 3	US	National Cancer Institute	08 Jun 2023
Squamous cell carcinoma of the hypopharynx	Phase 3	US	National Cancer Institute	08 Jun 2023
Squamous Cell Carcinoma of the Larynx	Phase 3	US	National Cancer Institute	08 Jun 2023
Squamous cell carcinoma of the oral cavity	Phase 3	US	National Cancer Institute	08 Jun 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04656041 (ASCO_GI2025)	Phase 2	Locally Advanced Gastroesophageal Junction Adenocarcinoma Neoadjuvant	40	Neoadjuvant NALIRIFOX	xlnknehgxn(mkxlvderkm) = 55%, 35%, and 13% respectively ggnnnftkml (fiefvncbrp ) View more	Positive	23 Jan 2025
				Chemoradiation with Paclitaxel and Carboplatin
ASCO_GI2025	Not Applicable	Neoplasm Metastasis \| Stomach Cancer	855	Intraperitoneal Paclitaxel-based regimens	dtzqrfinlf(ihadgspnnf) = yfjxcunjlz rrsicanfnh (jasfrwseuv, 66 - 76) View more	Positive	23 Jan 2025
				paclitaxel (Conversion Gastrectomy)	dtzqrfinlf(ihadgspnnf) = fkjvoyikbx rrsicanfnh (jasfrwseuv, 77 - 89) View more
ASCO_GI2025	Not Applicable	-	-	Intraperitoneal paclitaxel + Intravenous paclitaxel + S-1 (NIPS Group)	frkenmuwkk(sdkkquunpq) = pcaznlborh hgwxlkdbve (vwswlyzxwr ) View more	-	23 Jan 2025
				Intravenous paclitaxel + S-1 (PS Group)	frkenmuwkk(sdkkquunpq) = gxulgpezah hgwxlkdbve (vwswlyzxwr ) View more
ASCO_GI2025	Not Applicable	Metastatic Gastric Carcinoma CD326 \| CD45 \| CD8 ... View more	41	Intraperitoneal Paclitaxel	ktemzvdtbg(kgchzgsxda) = jvsscgcjmy kaadzesshs (dfqraaljfa ) View more	-	23 Jan 2025
				Control Group (No Intraperitoneal Paclitaxel)	ktemzvdtbg(kgchzgsxda) = byfgxvyqtv kaadzesshs (dfqraaljfa )
NCT04175912 (CTgov)	Phase 2	Unresectable Intrahepatic Cholangiocarcinoma \| Unresectable Hepatocellular Carcinoma \| Metastatic hepatocellular carcinoma ... View more	40	Pevonedistat (Arm A (Pevonedistat))	gdezhhpupz(eowyxxwqzw) = vksyhgzwri rqzbsdamci (mwjlffzycf, dgybqszppg - kgkvfbhkch) View more	-	07 Jan 2025
				Carboplatin+Paclitaxel+Pevonedistat (Arm B (Pevonedistat, Paclitaxel, Carboplatin))	gdezhhpupz(eowyxxwqzw) = qeohhtojxk rqzbsdamci (mwjlffzycf, tahnixbacw - nzatrfvvpn) View more
NCT01897441 (CTgov)	Not Applicable	Metastatic breast cancer \| Breast Cancer 3 \| Advanced breast cancer	31	Cytology Specimen Collection Procedure+Trastuzumab+cyclophosphamide+Doxorubicin Hydrochloride+Paclitaxel (Stratum A: HER2-positive)	henaodzcjv(oyzqpowcky) = uiqsqfooej zlqqneeckq (ksidgivpbb, dsrttkwvrc - hjvjcqglkq) View more	-	24 Dec 2024
				Cytology Specimen Collection Procedure+cyclophosphamide+Doxorubicin Hydrochloride+Paclitaxel (Stratum B: HER2-negative)	henaodzcjv(oyzqpowcky) = qnlymqozjy zlqqneeckq (ksidgivpbb, okwwdxdskf - lagalqrpew) View more
ESMO_ASIA2024 Manual	Not Applicable	Head and Neck Neoplasms	104	Docetaxel plus Cisplatin	crxecezoci(usqmtbsxgb) = dotwjnxfuh xqrxqgfuwh (ehbrslsnyl ) View more	Similar	07 Dec 2024
				Paclitaxel plus Carboplatin	crxecezoci(usqmtbsxgb) = rshwxpkwkx xqrxqgfuwh (ehbrslsnyl ) View more
ESMO_ASIA2024	Not Applicable	Squamous Cell Carcinoma	-	Paclitaxel plus carboplatin plus cetuximab (IC-PCE)	jjrakygqcy(ckywhvzzyu) = mzsudtfkju scxlgbtazb (jfclqavzff )	Positive	07 Dec 2024
				Docetaxel plus cisplatin plus S-1 (IC-TPS)	jjrakygqcy(ckywhvzzyu) = hgylpvestc scxlgbtazb (jfclqavzff )
ESMO_ASIA2024	Not Applicable	Extramammary Paget Disease First line Serum lactate dehydrogenase level \| carcinoembryonic antigen levels	12	Paclitaxel 80 mg/m2	yegzhbpgml(pdqfziwydp) = njkoacxump rvseahjpkm (ryngylrjce ) View more	Positive	07 Dec 2024
NCT02312245 (CTgov)	Phase 2	Platinum-Resistant Fallopian Tube Carcinoma \| Recurrent ovarian cancer \| Recurrent Primary Peritoneal Carcinoma	13	Paclitaxel+Bevacizumab (Arm A (Avatar-directed Paclitaxel))	qlsacfawiq(xgmpvjwkpv) = cnnwqsijyq vjvzpurjly (vuytepeudb, vwjneezezj - hjbhlwrbzb) View more	-	05 Dec 2024
				Gemcitabine Hydrochloride (Arm B (Avatar-directed Gemcitabine Hydrochloride))	qlsacfawiq(xgmpvjwkpv) = dggqowgpmv vjvzpurjly (vuytepeudb, hgtigbkiic - uvjiwmnkia) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis